Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Align Technology

Insulet

Investors are optimistic about a potential federal stimulus bill.

Why Align Technology, Insulet, and Intuitive Surgical Stocks Are Soaring Today

ISRG stock has skidded this year, leading Intuitive Surgical stock performance to lag its peers in its medical technology group. So, is it time to take on this robotic surgery stock?

This Robotic Surgery Behemoth Hit A Speed Bump — Is ISRG Stock A Buy?

Teladoc

Despite the current chaos in the stock market, these two healthcare stocks could be winners in the long run.

2 Healthcare Stocks to Buy in the Coronavirus Bear Market

Inuitive Surgical: Buying With Both Hands

F5 Networks

Johnson & Johnson

Microsoft

Regeneron Pharmaceuticals

Jeff Reeves lists stocks that should be relatively safe as business conditions threaten some companies with bankruptcy

Jeff Reeves's Strength in Numbers: These are the five most financially sound companies amid a cash crunch

Intuitive Surgical stock has fared better than the broader markets through the current crisis, and it will likely bounce back strongly and potentially outperform the broader markets, when the crisis winds down. For perspective, the stock rose over 300% between March 2009 and January 2010.

Can Intuitive Surgical Stock Outperform The Broader S&P 500 After Coronavirus?

Alnylam Pharmaceuticals

ResMed

Three words: Coronavirus market meltdown.

Why Alnylam Pharmaceuticals, Intuitive Surgical, and ResMed Stocks Sank Today

Gilead Sciences

Vertex Pharmaceuticals

Three steps you can take to follow Warren Buffett's advice and achieve extraordinary long-term results.

How to Be Greedy When Others Are Fearful

Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, stiff competition remains a woe.

Here's Why You Should Invest in Intuitive Surgical Stock Now

Looking for great stocks to buy if the market rebounds in a big way? Think healthcare.

3 Top Healthcare Stocks to Buy in March

Visa

If competitive advantages are your thing, then this list of brand-name businesses is for you.

3 Top Stocks That Will Make You Richer in March (and Beyond)

Abbott Labs

Baxter

Boston Scientific

Hill-Rom Hlds

Medtronic

Perrigo

Stryker

Zimmer Biomet Hlds

Medical Products Industry Outlook: Growth Prospects Bright

There is an upside of over 6% for Intuitive Surgical’s stock, in our view. We estimate Intuitive Surgical’s fair price estimate to be around $652, based on expected EPS of $14.59 on an adjusted basis for full year 2020 and price to earnings multiple of 44.7x.

What’s The Upside For Intuitive Surgical’s Stock?

Which stock wins in a matchup between these healthcare juggernauts?

Better Buy: Intuitive Surgical vs. Johnson & Johnson

bluebird bio

Bristol-Myers

It's not just their cancer treatments that make these stocks attractive.

3 Cancer Treatment Stocks  to Buy Right Now

The robotic surgery leader is facing potential headwinds but should continue making progress in 2020.

Even With Some Risks, Intuitive Surgical Will See Solid Growth in 2020

ISRG stock skidded in January, leading Intuitive Surgical stock performance to lag its peers in its medical technology industry group. So, is it time to take on this robotic surgery stock?

ISRG Stock: Should You Invest In The Biggest Robotic Surgery Player?

Intuitive Surgical: High Growth Potential In Surgery, And Beyond

Amazon

Bank of America

Innovative Industrial Properties

Pinterest

AT&T

It's easy to adore these great businesses.

7 Stock Market Sweethearts You'll Want to Call Your Own

The robotic surgical systems pioneer is making a big move beyond its core business.

Intuitive Surgical Expands Into Hospital Informatics With Orpheus Medical Acquisition

Intuitive Surgical Captures A Revolutionary Secular Growth Trend

SUNNYVALE, Calif., Feb.  03, 2020  (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that Lonnie M. Smith has decided to retire from the company’s board of directors when his term ends at the company’s 2020 annual meeting of stockholders, currently scheduled for April. Mr. Smith will join the board of directors of the Intuitive Foundation after his retirement.

Intuitive Announces Retirement of Board Chair Lonnie M. Smith; Dr.

Here is why Intuitive Surgical’s future still looks bright.

Intuitive Surgical Shows No Signs of Slowing Down

Another guidance hangup is creating an opportunity for investors looking more than a few quarters into the future.

Why Intuitive Surgical Is a Buy After Reporting Q4 2019 Earnings

Intuitive Surgical stock skidded in high volume Friday after the robotic surgery company issued a conservative 2020 outlook for procedure growth following a slowdown in the fourth quarter.

News for Intuitive Surgical Stock (ISRG)